Inclusion Criteria:

• - Diagnosed with RRMS per revised McDonald criteria (2017) with an EDSS score ≤ 6.5 at screening.

• - Neurologically stable with no evidence of relapse within the 28 days before signing the informed consent form (ICF) - Either not currently receiving disease modifying MS therapy, or currently using fumarate drugs (dimethyl fumarate or diroximel fumarate) - Patients must use a highly effective method of birth control or are sterile or postmenopausal as confirmed by study Investigator.

• - Patient has signed and understands the ICF.

Exclusion Criteria:

• - Diagnosis of primary progressive MS or secondary progressive MS.

• - Uncontrolled or significant medical conditions (including active infection or chronic hepatitis) which, in the opinion of the Investigator, preclude participation.

• - Patients treated with glatiramer acetate, parenteral steroids or adrenocorticotropic hormone, β-interferon, plasma exchange within the 3 months prior to first dose.

• - Patients treated with sphingosine-1-phospate receptor modulators such as fingolimod, ozanimod, or siponimod within 6 months prior to first dose.

• - Patients treated with cytotoxic agents (including, but not limited to, cladribine, mitoxantrone, cyclophosphamide, azathioprine, and methotrexate), laquinimod, teriflunomide, or IV gamma globulin within 12 months prior to first dose.

• - Patients treated with monoclonal antibody therapy (including natalizumab, daclizumab, rituximab, ofatumumab, and ocrelizumab) within 24 months prior to first dose.

• - Patients previously treated with alemtuzumab, total lymphoid irradiation, mesenchymal stem cell or hematopoietic stem cell transplantation, or tolerance-inducing therapies for MS.

• - Contraindication to or inability to undergo gadolinium-enhanced magnetic resonance imaging (MRI) scan.

• - Use of any investigational drug or experimental procedure within previous 6 months that would interfere with the assessment of ANK-700.

• - Patients who are pregnant or breastfeeding.

• - Patients receiving any vaccination within 28 days prior to first dose.

- Patient does not agree to limit alcohol intake to 2 drink equivalents or less per day during the study

Study ANK-700-01 is a Phase 1, FIH study designed to evaluate the safety and tolerability of ANK-700 in patients with relapsing remitting multiple sclerosis (rrms). An overview of the two parts and proposed dose groups is given below: Part A (SAD): Patients will receive a single dose of ANK-700. Part B (MAD): Patients will receive three doses of either ANK-700 or placebo.

Arms

Experimental: ANK-700 SAD Cohort 1, Dose A

All enrolled patients will receive one dose of ANK-700 Dose A

Experimental: ANK-700 SAD Cohort 2, Dose B

All enrolled patients will receive one dose of ANK-700 Dose B

Experimental: ANK-700 SAD Cohort 3 Dose C

All enrolled patients will receive one dose of ANK-700 Dose C

Experimental: MAD Cohort 4 ANK-700 Dose A or Placebo

All enrolled patients will receive three doses of ANK-700 Dose A or placebo

Experimental: MAD Cohort 5 ANK-700 Dose B or placebo

All enrolled patients will receive three doses of ANK-700 Dose B or placebo

Interventions

Drug: - ANK-700

Intravenous (IV) infusion

Drug: - Placebo

Intravenous (IV) infusion